CM336

DRUG3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Keymed Biosciences Co.Ltd

Conditions

High Risk Smoldering Multiple MyelomaPlasma Cell Leukemia (PCL)Primary Sjögren's Syndrome (pSS)

Phase 1

CM336 for Active Sjogren's Syndrome Study

Not yet recruitingNCT07642843

Keymed Biosciences Co.LtdPrimary Sjögren's Syndrome (pSS)

Start: 2026-06-01End: 2029-02-01Target: 30Updated: 2026-06-12

Phase 2

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

Not yet recruitingNCT07652905

Institute of Hematology & Blood Diseases Hospital, ChinaPlasma Cell Leukemia (PCL)

Start: 2026-06-20End: 2031-12-30Target: 24Updated: 2026-06-17

Unknown Phase

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

RecruitingNCT06745687

Institute of Hematology & Blood Diseases Hospital, ChinaHigh Risk Smoldering Multiple Myeloma

Start: 2024-12-30End: 2029-08-01Target: 20Updated: 2026-07-23